EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Evaluating anti-sickling therapies for sickle cell disease: a microfluidic assay for red blood cell-mediated microvascular occlusion under hypoxia

Zoe Sekyonda iD, Yuxuan Du iD, Solomon Oshabaheebwa iD, Payam Fadaei iD, Yusang B Ley, Calvin Abonga iD, Michael A Suster iD, Pedram Mohseni iD, Umut A Gurkan iD

Lab on a Chip · 2025

DOI: 10.1039/d5lc00264h ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lab on a Chip, 2025. Verfasst von Zoe Sekyonda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Erythrocytes, Microfluidic Analytical Techniques, Lab-On-A-Chip Devices. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: FIC NIH HHS, NHLBI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study establishes the chemically induced hypoxia OcclusionChip assay as a reliable clinical tool for evaluating red blood cell deformability in sickle cell disease, with potential to improve personalized treatment strategies and outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellErythrocytesMicrofluidic Analytical TechniquesLab-On-A-Chip DevicesAntisickling AgentsHumansErythrocyte DeformabilityCell Hypoxia

Substanzen

Antisickling Agents

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
  • Department of Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH, USA. umut@case.edu.
  • Department of Electrical, Computer, and Systems Engineering, Case Western Reserve University, Cleveland, OH, USA.
  • Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.

ORCID-Profile: Zoe Sekyonda, Yuxuan Du, Solomon Oshabaheebwa, Payam Fadaei, Calvin Abonga, Michael A Suster, Pedram Mohseni, Umut A Gurkan

Förderung

  • FIC NIH HHS
  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • Small Business Innovation Research
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • American Society of Hematology
  • Fogarty International Center

Zitieren

APA

Sekyonda, Z., Du, Y., Oshabaheebwa, S., Fadaei, P., Ley, Y. B., Abonga, C., Suster, M. A., Mohseni, P., & Gurkan, U. A. (2025). Evaluating anti-sickling therapies for sickle cell disease: a microfluidic assay for red blood cell-mediated microvascular occlusion under hypoxia. Lab on a Chip. https://doi.org/10.1039/d5lc00264h

Vancouver

Sekyonda Z, Du Y, Oshabaheebwa S, Fadaei P, Ley YB, Abonga C, et al. Evaluating anti-sickling therapies for sickle cell disease: a microfluidic assay for red blood cell-mediated microvascular occlusion under hypoxia. Lab on a Chip. 2025. doi:10.1039/d5lc00264h

BibTeX
@article{Sekyonda2025,
  author = {Sekyonda, Zoe and Du, Yuxuan and Oshabaheebwa, Solomon and Fadaei, Payam and Ley, Yusang B and Abonga, Calvin and Suster, Michael A and Mohseni, Pedram and Gurkan, Umut A},
  title = {Evaluating anti-sickling therapies for sickle cell disease: a microfluidic assay for red blood cell-mediated microvascular occlusion under hypoxia},
  journal = {Lab on a Chip},
  year = {2025},
  doi = {10.1039/d5lc00264h}
}
Kostenlos starten →